Built to Last: Taiwan’s Family-Owned Pharmas
Taiwan runs one of the most cost-effective universal healthcare systems in the world, delivering near-universal coverage to 23 million people at a fraction of what comparable systems cost elsewhere. At…
With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals – has undoubtedly intensified. Yet the industry continues to wield a…
Taiwan runs one of the most cost-effective universal healthcare systems in the world, delivering near-universal coverage to 23 million people at a fraction of what comparable systems cost elsewhere. At…
A sustainable market for generics and biosimilars is the key to lowering the cost of medicine in the US, says John Murphy III, President and CEO of the Association for…
For over two decades, Europe’s pharmaceutical manufacturing footprint has steadily shifted offshore towards countries like China and India, driven by the pursuit of lower costs and operational efficiencies. However, the…
The future of Europe’s pharmaceutical industry will be shaped as much by manufacturing and industrial policy as by scientific innovation. Theodore Tryfon outlines how ELPEN is investing to strengthen healthcare resilience, expand internationally and support Greece’s emergence as a strategic pharmaceutical manufacturing hub, while reflecting on the policy choices that will determine Europe’s long-term competitiveness. We believe resilient supply…
Petar Vazharov, CEO of Lotus Pharmaceuticals, is a medical doctor with an MBA who joined Alvogen in 2009 as one of its first international hires. After building the company’s Central…
Few European pharmaceutical companies have undergone a transformation as striking as STADA’s. From its roots as a German generics business, the group has evolved into a diversified healthcare player with…
Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche…
As healthcare systems grapple with rising costs and the need for broader access to treatment, off-patent medicines have taken on increasing importance. With budgets under pressure and blockbuster drugs losing…
John Murphy, III, president & CEO of the Association for Accessible Medicines (AAM) lays out a stark warning: the very medicines that keep the US healthcare system affordable and functioning…
Will a new ‘Critical Medicines Act’ go far enough to ensure Europe’s resilience to future health crises? A Continent at Risk The COVID-19 pandemic exposed serious vulnerabilities in the…
Amidst the hype of Saudi Arabia’s embrace of innovative therapies and technologies, the concepts of access and affordability can often be forgotten. However, the Saudi government remains the dominant healthcare…
Rock-bottom prices, regulatory red tape, and intense competition from Asia have made life difficult for Europe’s generics and biosimilar producers. Yet a handful of companies are not just surviving this…
See our Cookie Privacy Policy Here
